



EY Entrepreneur
of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013



March 20, 2025

To,
Mr. Amit Shinde
Chief Manager
Surveillance
National Stock Exchange of India Limited (NSE).
Exchange Plaza, Bandra Kurla Complex, Bandra
East, Mumbai – 400051

Scrip Code: ERIS

Dear Sir,

Sub: Reply to the clarification sought on Increase in Volume of the shares of the company

This is with reference to your email dated March 20, 2025, seeking clarification for significant increase in the Volume of our Security across the Exchanges. In this regards, we wish to inform you that all the material information / announcement that may have bearing on the operations / performance of the Company which include all the necessary disclosures in accordance with regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and under insider trading regulation, have always been disclosed by the Company within stipulated time and the same is available in public domain. There is no pending information or announcements which have a bearing on the increase in price/volume of security of the Company.

Therefore, the increase in volume of our security is purely due to market conditions and absolutely market driven and the Company is in no way connected with any such increase in volume.

We hope the above clarifies and request you to kindly take the same on your records.

Thanking you,

For Eris Lifesciences Limited

Milind Talegaonkar
Company Secretary & Compliance Officer
ICSI Membership No.: A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867